Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR091506 in gout with hyperuricemia
NCT06139393Phase 3Completed
- Sponsor
- Hengrui
- Start
- Dec 2023
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gout and hyperuricemia comparing HR091506 + placebo with Febuxostat + placebo (2 arms). Primary endpoint: Proportion of subjects with serum uric acid level < 360 μmol/L at Week 28. Started Dec 2023; status: completed.
02
Drugs
HR091506
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT06139393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06139393.